tiprankstipranks
Blurbs

Incyte (INCY) Receives a Buy from JMP Securities

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Incyte (INCYResearch Report), with a price target of $108.00. The company’s shares closed last Wednesday at $68.28.

According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.2% and a 30.5% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $90.36, a 35.2% upside from current levels. In a report issued on February 8, Truist Financial also reiterated a Buy rating on the stock with a $95.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $94.50 and a one-year low of $61.91. Currently, Incyte has an average volume of 2.21M.

Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Read More on INCY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed